{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:33:51Z","timestamp":1784745231309,"version":"3.55.0"},"reference-count":51,"publisher":"The Endocrine Society","issue":"11","funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["NIH-P30-AR072577"],"award-info":[{"award-number":["NIH-P30-AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Teriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates. However, limited head-to-head comparative effectiveness data exist between teriparatide and denosumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We compared changes in bone mineral density (BMD) between groups treated with teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on either drug over 2 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Observational cohort study using electronic medical records from two academic medical centers in the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>The study population included osteoporotic patients &gt;45 years who received bisphosphonates &gt;1 year before switching to teriparatide or denosumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome Measures<\/jats:title>\n                  <jats:p>Annualized BMD change from baseline at the lumbar spine, total hip, and femoral neck.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients treated with teriparatide (n = 110) were compared with those treated with denosumab (n = 105); the mean (SD) age was 70 (10) years and median duration (interquartile range) of bisphosphonate use was 7.0 (5.6 to 9.7) years. Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by \u22122.2% (95% CI \u22122.9 to \u22121.5%) and the femoral neck by \u22121.1% (95% CI \u22122.1 to \u22120.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients who use long-term bisphosphonates, the decision of switching to teriparatide should be made with caution, especially for patients at high risk of hip fracture.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-00924","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T09:02:58Z","timestamp":1562058178000},"page":"5611-5620","source":"Crossref","is-referenced-by-count":40,"title":["Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-0062","authenticated-orcid":false,"given":"Houchen","family":"Lyu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Orthopedics, Chinese People\u2019s Liberation Army General Hospital, Beijing, China"},{"name":"China National Clinical Research Center of Musculoskeletal Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizheng S","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"issue":"10","key":"2019101003035871600_bib1","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis [published correction appears in Osteoporos Int. 2015;26(7):2045\u20132047]","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"10","key":"2019101003035871600_bib2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archinte.168.10.1111","article-title":"Osteoporosis medication use in nursing home patients with fractures in 1 US state","volume":"168","author":"Parikh","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019101003035871600_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-016-0285-0","article-title":"Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries","volume":"11","author":"Yusuf","year":"2016","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2019101003035871600_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11657-018-0439-3","article-title":"Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women","volume":"13","author":"Yusuf","year":"2018","journal-title":"Arch Osteoporos"},{"issue":"8","key":"2019101003035871600_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis [published correction appears in N Engl J Med. 2009;361(19):1914]","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"2019101003035871600_bib6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2019101003035871600_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019101003035871600_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"2019101003035871600_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"2019101003035871600_bib10","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019101003035871600_bib11","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1210\/jc.2015-1715","article-title":"Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate","volume":"100","author":"Cosman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019101003035871600_bib12","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019101003035871600_bib13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1210\/jc.2018-02236","article-title":"Comparison of denosumab vs. bisphosphonates in osteoporosis patients: a meta-analysis of randomized controlled trials","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019101003035871600_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00198-014-2971-3","article-title":"Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis","volume":"26","author":"Bonafede","year":"2015","journal-title":"Osteoporos Int"},{"issue":"9","key":"2019101003035871600_bib15","first-page":"824","article-title":"Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States","volume":"21","author":"Cheng","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"9886","key":"2019101003035871600_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"2019101003035871600_bib17","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis","volume":"99","author":"Mandema","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2019101003035871600_bib18","unstructured":"Lyu\n              H\n            , ZhaoS, YoshidaK, TedeschiSK, XuC, NigwekarSU, LederBZ, SolomonDH. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. figshare 2019. Deposited 10 June 2019. https:\/\/dx.doi.org\/10.6084\/m9.figshare.8248682.v3"},{"issue":"11","key":"2019101003035871600_bib19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"9","key":"2019101003035871600_bib20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019101003035871600_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat"},{"issue":"3","key":"2019101003035871600_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"521","key":"2019101003035871600_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc"},{"issue":"18","key":"2019101003035871600_bib24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"13","key":"2019101003035871600_bib25","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2019101003035871600_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2019101003035871600_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"key":"2019101003035871600_bib28","unstructured":"Lyu\n              H\n            , ZhaoSS, YoshidaK, TedeschiSK, XuC, NigwekarSU, LederBZ, SolomonDH. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. figshare 2019. Deposited 10 June 2019. https:\/\/dx.doi.org\/10.6084\/m9.figshare.8248709.v5"},{"key":"2019101003035871600_bib29","unstructured":"Lyu\n              H\n            , ZhaoSS, YoshidaK, TedeschiSK, XuC, NigwekarSU, LederBZ, SolomonDH. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. figshare 2019. Deposited 10 June 2019. https:\/\/dx.doi.org\/10.6084\/m9.figshare.8248715.v3"},{"key":"2019101003035871600_bib30","unstructured":"Lyu\n              H\n            , ZhaoSS, YoshidaK, TedeschiSK, XuC, NigwekarSU, LederBZ, SolomonDH. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. figshare 2019. Deposited 10 June 2019. https:\/\/dx.doi.org\/10.6084\/m9.figshare.8248724.v2"},{"key":"2019101003035871600_bib31","author":"Black"},{"issue":"3","key":"2019101003035871600_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2019101003035871600_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2019101003035871600_bib34","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"issue":"8","key":"2019101003035871600_bib35","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int"},{"issue":"4","key":"2019101003035871600_bib36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT","volume":"28","author":"Hansen","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019101003035871600_bib37","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019101003035871600_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019101003035871600_bib39","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019101003035871600_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/BOR.0000000000000509","article-title":"Long-term treatment strategies for postmenopausal osteoporosis","volume":"30","author":"Cosman","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"2019101003035871600_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"issue":"6","key":"2019101003035871600_bib42","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019101003035871600_bib43","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2019101003035871600_bib44","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2019101003035871600_bib45","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1210\/jc.2014-1041","article-title":"Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study","volume":"99","author":"Nishiyama","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2019101003035871600_bib46","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019101003035871600_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"issue":"6","key":"2019101003035871600_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"2019101003035871600_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2019101003035871600_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2019101003035871600_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2014 2016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00924\/28893260\/jc.2019-00924.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5611\/30124741\/jc.2019-00924.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5611\/30124741\/jc.2019-00924.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T03:08:36Z","timestamp":1570676916000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/11\/5611\/5526755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00924","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,7,2]]}}}